FY2025 EPS Estimates for SPRY Cut by Cantor Fitzgerald

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for ARS Pharmaceuticals in a research note issued on Thursday, May 15th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will earn ($1.44) per share for the year, down from their previous estimate of ($1.21). The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.35). The business had revenue of $7.97 million during the quarter, compared to analysts' expectations of $7.48 million.

SPRY has been the topic of a number of other reports. Oppenheimer assumed coverage on shares of ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an "outperform" rating and a $40.00 target price on the stock. Scotiabank assumed coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price objective on the stock. Finally, William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, ARS Pharmaceuticals has an average rating of "Buy" and an average target price of $31.00.

ARS Pharmaceuticals Price Performance

SPRY stock opened at $13.60 on Monday. ARS Pharmaceuticals has a 12 month low of $7.55 and a 12 month high of $18.51. The firm's 50-day moving average is $13.34 and its 200 day moving average is $12.86. The company has a market capitalization of $1.34 billion, a PE ratio of -26.67 and a beta of 0.84.

Insider Buying and Selling

In other news, Director Laura Shawver sold 49,600 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $11.21, for a total transaction of $556,016.00. Following the completion of the sale, the director now owns 210,346 shares in the company, valued at approximately $2,357,978.66. This represents a 19.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Eric Karas sold 10,000 shares of the firm's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the sale, the insider now directly owns 7,696 shares of the company's stock, valued at $107,744. The trade was a 56.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,602 shares of company stock valued at $1,311,041 over the last 90 days. Corporate insiders own 33.50% of the company's stock.

Hedge Funds Weigh In On ARS Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bernard Wealth Management Corp. acquired a new stake in shares of ARS Pharmaceuticals during the fourth quarter worth $27,000. ANTIPODES PARTNERS Ltd purchased a new stake in ARS Pharmaceuticals in the first quarter valued at approximately $37,000. PNC Financial Services Group Inc. boosted its position in ARS Pharmaceuticals by 78,100.0% in the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company's stock valued at $49,000 after buying an additional 3,905 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in ARS Pharmaceuticals in the 4th quarter worth approximately $73,000. Finally, BNP Paribas Financial Markets purchased a new position in ARS Pharmaceuticals during the 4th quarter worth approximately $75,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.